Trial Profile
A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- 18 Sep 2022 Planned End Date changed from 31 Aug 2023 to 4 Oct 2026.
- 18 Sep 2022 Planned primary completion date changed from 31 Aug 2022 to 4 Oct 2026.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition